Consultant Rheumatologist, Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece.
Semin Arthritis Rheum. 2010 Apr;39(5):369-83. doi: 10.1016/j.semarthrit.2008.10.008. Epub 2008 Dec 18.
During the last decade research has focused on the RANK-RANKL-OPG (Receptor Activator of Nuclear factor KappaB-Receptor Activator of Nuclear factor KappaB Ligand-Osteoprotegerin) pathway that is currently considered the final common route to bone and joint remodeling. The potential role of novel additional mediators has been highlighted by several reports. This review focuses on the recent information about the pathophysiology of the Wingless (Wnt) pathway and interleukin-17 (IL-17) in relation of their role in bone and joint remodeling.
An extensive internet search was performed (PubMed) from 1998 and onward using the following keywords: Wnt, bone remodeling, bone, rheumatic diseases, rheumatoid arthritis, IL-17, Th17, osteoblastogenesis, and osteoclastogenesis.
Several members of the Wnt pathway play an important role in bone remodeling. Recent experimental data indicate a key role for Dickkopf-1, a soluble inhibitor of the Wnt pathway, in bone remodeling. Increased Dickkopf-1 levels are linked to bone resorption and decreased levels to new bone formation. Low-density lipoprotein receptor-related protein-5, the main receptor that mediates Wnt signaling, plays a critical role in bone mass regulation. Gain-of-function mutations of lipoprotein receptor-related protein-5 cause high bone mass phenotypes, whereas loss-of-function mutations are linked to severe osteoporosis. IL-17 is a proinflammatory cytokine that is produced by a recently described T-cell subset, known as Th17 cells. Evidence suggests that IL-17 is a critical mediator of joint destruction in animal models of arthritis. IL-17 blockade has beneficial effects on murine arthritis, a fact that points to the direction of this cytokine as a potential therapeutic target in human inflammatory arthritides as well.
The available data suggest that mediators in these 2 biologic systems are critical in joint remodeling and may be appropriate targets in the treatment of bone and joint abnormalities that characterize a variety of inflammatory arthritides and bone diseases.
在过去的十年中,研究的重点集中在 RANK-RANKL-OPG(核因子 κB 受体激活剂-核因子 κB 受体激活剂配体-骨保护素)途径上,该途径目前被认为是骨骼和关节重塑的最终共同途径。一些报告强调了新的额外介质的潜在作用。这篇综述重点介绍了 Wnt 途径和白细胞介素 17(IL-17)在骨骼和关节重塑中的作用的最新病理生理学信息。
从 1998 年开始,通过广泛的互联网搜索(PubMed),使用以下关键词搜索了以下关键词:Wnt、骨重塑、骨、风湿性疾病、类风湿关节炎、IL-17、Th17、成骨细胞生成和破骨细胞生成。
Wnt 途径的几个成员在骨重塑中起着重要作用。最近的实验数据表明,Wnt 途径的可溶性抑制剂 Dickkopf-1 在骨重塑中起着关键作用。Dickkopf-1 水平的增加与骨吸收有关,而水平的降低与新骨形成有关。低密度脂蛋白受体相关蛋白-5 是介导 Wnt 信号的主要受体,在骨量调节中起着关键作用。脂蛋白受体相关蛋白-5 的功能获得性突变导致高骨量表型,而功能丧失性突变与严重骨质疏松症有关。白细胞介素 17 是一种促炎细胞因子,由一种新描述的 T 细胞亚群,即 Th17 细胞产生。有证据表明,白细胞介素 17 是关节炎动物模型中关节破坏的关键介质。白细胞介素 17 阻断对鼠关节炎有有益的影响,这一事实表明该细胞因子是人类炎症性关节炎的潜在治疗靶点。
现有数据表明,这两个生物系统中的介质在关节重塑中至关重要,并且可能是治疗各种炎症性关节炎和骨病特征性骨和关节异常的合适靶点。